Psyence Biomedical (PBM) Total Debt (2023 - 2024)
Psyence Biomedical (PBM) posted Total Debt of $1.3 million for Q3 2024, down 15.02% on a QoQ basis from $1.5 million in Q1 2024, and down 37.35% year-over-year from $2.0 million in Q4 2023.
Powered by 
Analysis
Psyence Biomedical (PBM) Total Debt (2023 - 2024) Analysis & Trends
Psyence Biomedical has reported Total Debt for 2 years, with the latest figure at $1.3 million in Q3 2024.
- On a quarterly basis, Total Debt fell 37.35% year-over-year to $1.3 million in Q3 2024; TTM through Sep 2024 was $1.3 million, a 37.35% decrease from a year earlier, with the FY2024 full-year figure at $1.5 million, changed N/A from the prior year.
- Total Debt was $1.3 million for Q3 2024 at Psyence Biomedical, down from $1.5 million in the prior quarter.
- The five-year high for Total Debt was $2.0 million in Q3 2023, with the low at $1.3 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn | 62.75 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 28.66 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 8.09 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | - |
| 10 | Psyence Biomedical | 2.63 Mn | 2.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 1.25 Mn |
| Mar 31, 2024 | 1.47 Mn |
| Sep 30, 2023 | 2.00 Mn |